ARQT Quote, Financials, Valuation and Earnings

Mirum Pharmaceuticals has a net margin of -92.81% compared to Arcutis Biotherapeutics's net margin of -15.75%. Arcutis Biotherapeutics's return on equity of -138.99% beat Mirum Pharmaceuticals's return on equity of -41.13%.

Arcutis Biotherapeutics has a consensus price target of $19.00, signalling upside risk potential of 26.75%. On the other hand Mirum Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 49.4%. Given that Mirum Pharmaceuticals has higher upside potential than Arcutis Biotherapeutics, analysts believe Mirum Pharmaceuticals is more attractive than Arcutis Biotherapeutics.

Arcutis Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mirum Pharmaceuticals has a beta of 1.200, suggesting its more volatile than the S&P 500 by 19.974%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. Mirum Pharmaceuticals pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $44.8M, which are smaller than Mirum Pharmaceuticals quarterly revenues of $90.4M. Arcutis Biotherapeutics's net income of -$41.5M is lower than Mirum Pharmaceuticals's net income of -$14.2M. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while Mirum Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 12.31x versus 6.47x for Mirum Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -92.81% compared to Arcutis Biotherapeutics's net margin of -49.65%. Arcutis Biotherapeutics's return on equity of -138.99% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Arcutis Biotherapeutics has a consensus price target of $19.00, signalling upside risk potential of 26.75%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Arcutis Biotherapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Arcutis Biotherapeutics.

Arcutis Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $44.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Arcutis Biotherapeutics's net income of -$41.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 12.31x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -92.81% compared to Arcutis Biotherapeutics's net margin of -2357.27%. Arcutis Biotherapeutics's return on equity of -138.99% beat Palatin Technologies's return on equity of --.

Arcutis Biotherapeutics has a consensus price target of $19.00, signalling upside risk potential of 26.75%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Arcutis Biotherapeutics, analysts believe Palatin Technologies is more attractive than Arcutis Biotherapeutics.

Arcutis Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $44.8M, which are larger than Palatin Technologies quarterly revenues of $350K. Arcutis Biotherapeutics's net income of -$41.5M is lower than Palatin Technologies's net income of -$7.8M. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 12.31x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -92.81% compared to Arcutis Biotherapeutics's net margin of 37.71%. Arcutis Biotherapeutics's return on equity of -138.99% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Arcutis Biotherapeutics has a consensus price target of $19.00, signalling upside risk potential of 26.75%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.93%. Given that Arcutis Biotherapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Arcutis Biotherapeutics is more attractive than Vertex Pharmaceuticals.

Arcutis Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $44.8M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Arcutis Biotherapeutics's net income of -$41.5M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 12.31x versus 10.00x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.